Log in
NASDAQ:SRPT

Sarepta Therapeutics Stock Forecast, Price & News

$146.31
+3.47 (+2.43 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$140.94
Now: $146.31
$146.61
50-Day Range
$127.12
MA: $146.02
$159.04
52-Week Range
$72.05
Now: $146.31
$175.00
Volume402,835 shs
Average Volume870,472 shs
Market Capitalization$11.49 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.84
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company's pipeline comprise SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA. It has collaboration agreements with Nationwide Children's Hospital to advance micro-dystrophin gene therapy program under the research and license option agreement; Galgt2, a gene therapy program for the treatment of DMD; and Neutrophin 3, a gene therapy program to treat Charcot-Marie-Tooth neuropathies. The company also has a license agreement with Lysogene to develop LYS-SAF302, a gene therapy for mucopolysaccharidosis IIIA; a license and option agreement with Lacerta to develop treatments for CNS-targeted and lysosomal storage diseases; and research collaboration and option agreement with Genethon to develop micro-dystrophin gene therapy products. In addition, it has a research agreement with Duke University to advance gene editing CRISPR/Cas9 technology for restoring dystrophin expression; a collaboration agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline; a strategic collaboration with Paragon Bioservices; and a strategic collaboration with CENTOGENE for the identification of patients with DMD in the Middle East and North Africa region. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Read More
Sarepta Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.86 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRPT
Previous SymbolNASDAQ:AVII
CUSIPN/A
Phone617-274-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$380.83 million
Book Value$10.98 per share

Profitability

Net Income$-715,080,000.00
Net Margins-117.80%

Miscellaneous

Employees499
Market Cap$11.49 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$146.31
+3.47 (+2.43 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SRPT News and Ratings via Email

Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions

How has Sarepta Therapeutics' stock been impacted by Coronavirus?

Sarepta Therapeutics' stock was trading at $102.8150 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SRPT shares have increased by 42.3% and is now trading at $146.31.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Sarepta Therapeutics?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 2 hold ratings and 22 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Sarepta Therapeutics
.

When is Sarepta Therapeutics' next earnings date?

Sarepta Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Sarepta Therapeutics
.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics Inc (NASDAQ:SRPT) issued its quarterly earnings data on Wednesday, August, 5th. The biotechnology company reported ($1.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.73) by $0.20. The biotechnology company earned $137.36 million during the quarter, compared to analysts' expectations of $112.36 million. Sarepta Therapeutics had a negative net margin of 117.80% and a negative return on equity of 53.02%.
View Sarepta Therapeutics' earnings history
.

What price target have analysts set for SRPT?

24 Wall Street analysts have issued 12-month price targets for Sarepta Therapeutics' shares. Their forecasts range from $167.00 to $230.00. On average, they anticipate Sarepta Therapeutics' share price to reach $197.87 in the next twelve months. This suggests a possible upside of 35.2% from the stock's current price.
View analysts' price targets for Sarepta Therapeutics
.

Who are some of Sarepta Therapeutics' key competitors?

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the following people:
  • Mr. Douglas S. Ingram, Pres, CEO & Director (Age 56)
  • Mr. Sandesh Mahatme LL.M., Exec. VP, CFO & Chief Bus. Officer (Age 54)
  • Mr. David Tyronne Howton Jr., Exec. VP, Gen. Counsel & Corp. Sec. (Age 47)
  • Mr. Alexander Bo Cumbo, Exec. VP & Chief Commercial Officer (Age 48)
  • Dr. Edward M. Kaye, Advisor (Age 70)

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.07%), Gilder Gagnon Howe & Co. LLC (1.15%), First Trust Advisors LP (0.86%), Jennison Associates LLC (0.75%), Orbimed Advisors LLC (0.71%) and Macquarie Group Ltd. (0.67%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, M Kathleen Behrens, Michael W Bonney, Richard Barry and Sandesh Mahatme.
View institutional ownership trends for Sarepta Therapeutics
.

Which institutional investors are selling Sarepta Therapeutics stock?

SRPT stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Jennison Associates LLC, Cormorant Asset Management LP, Gilder Gagnon Howe & Co. LLC, Sumitomo Mitsui Trust Holdings Inc., WS Management Lllp, PNC Financial Services Group Inc., and Prudential Financial Inc.. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Alexander Cumbo, David T Howton, Hans Lennart Rudolf Wigzell, Joseph Bratica, Richard Barry, and Sandesh Mahatme.
View insider buying and selling activity for Sarepta Therapeutics
.

Which institutional investors are buying Sarepta Therapeutics stock?

SRPT stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Macquarie Group Ltd., First Trust Advisors LP, Bank of Montreal Can, Nuveen Asset Management LLC, Tobam, MUFG Securities EMEA plc, and State of Wisconsin Investment Board. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram, M Kathleen Behrens, Michael W Bonney, and Richard Barry.
View insider buying and selling activity for Sarepta Therapeutics
.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $146.31.

How big of a company is Sarepta Therapeutics?

Sarepta Therapeutics has a market capitalization of $11.49 billion and generates $380.83 million in revenue each year. The biotechnology company earns $-715,080,000.00 in net income (profit) each year or ($9.71) on an earnings per share basis. Sarepta Therapeutics employs 499 workers across the globe.

What is Sarepta Therapeutics' official website?

The official website for Sarepta Therapeutics is www.sareptatherapeutics.com.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.